What is the role of cilostazol in the management of peripheral arterial disease (PAD)?

Role of Cilostazol in Management of Peripheral Vascular Disease

Cilostazol 100 mg orally twice daily is the first-line pharmacological therapy for all patients with lifestyle-limiting intermittent claudication who do not have heart failure, and should be initiated as a therapeutic trial in conjunction with supervised exercise therapy. 1, 2, 3

Primary Indication and Dosing

Cilostazol is indicated specifically for symptomatic intermittent claudication to improve walking distance and reduce symptoms. 1, 4

• Standard dose: 100 mg orally twice daily, taken 30 minutes before or 2 hours after breakfast and dinner 3
• Do not start with lower doses: The 50 mg twice daily dose is less effective and not recommended as initial therapy 1, 3
• Treatment duration: Continue for minimum 12-24 weeks before assessing therapeutic benefit 1, 3
• Expected improvement: Walking distance increases by 40-60% compared to placebo after 12-24 weeks 1, 3

Absolute Contraindication

Heart failure of any severity is an absolute contraindication to cilostazol use. 1, 2, 3

• The FDA has mandated a black-box warning prohibiting use in patients with heart failure 1
• This stems from other phosphodiesterase III inhibitors (milrinone, vesnarinone) causing increased mortality in heart failure patients 1
• Cardiovascular mortality with cilostazol was 0.6% versus 0.5% with placebo at 6 months in patients without heart failure, showing no increased risk in appropriate candidates 1, 3

Mechanism and Effects

Cilostazol is a phosphodiesterase type 3 inhibitor with multiple vascular effects 1, 4:

• Platelet inhibition: Reversibly inhibits platelet aggregation induced by thrombin, ADP, collagen, and other stimuli 4
• Vasodilation: Produces non-homogeneous dilation of vascular beds, with greater effect in femoral arteries 4
• Lipid effects: Reduces triglycerides by 15% and increases HDL cholesterol by approximately 10% 1, 4
• Anti-inflammatory effects: Inhibits vascular cell adhesion molecule-1 expression and smooth muscle cell proliferation 1, 5

Monitoring and Assessment

Assess tolerance at 2-4 weeks and therapeutic benefit at 3-6 months to determine continuation. 3

• Approximately 20% of patients discontinue within first 3 months due to adverse effects 3
• Cilostazol modestly increases ankle-brachial index (ABI), but hemodynamic effects do not fully explain clinical improvement 1
• Heart rate increases by mean of 7.4 beats per minute with 100 mg twice daily 4

Common Adverse Effects

Headache is the most frequent side effect, occurring 2.8 times more often than placebo, but is generally mild and self-limited. 3

Other common adverse effects include 1, 3:

• Diarrhea and abnormal stools
• Palpitations
• Dizziness

These side effects have not been associated with serious safety concerns in clinical trials 1

Emerging Role After Endovascular Therapy

Cilostazol may be considered to reduce restenosis following femoropopliteal endovascular procedures (Class IIb recommendation). 3

Recent evidence supports additional benefits beyond claudication treatment:

• Restenosis prevention: Meta-analysis of randomized trials shows cilostazol reduces restenosis odds by 72% (OR 0.28) after endovascular therapy 6
• Target lesion revascularization: Reduces TLR odds by 65% (OR 0.35) in randomized studies 6, 7
• Amputation risk: Observational studies adjusting for confounders show 46% lower amputation rates (HR 0.54) 6, 8
• Primary patency: Improves primary patency after endovascular therapy (OR 2.28) independent of warfarin use 7

These benefits extend to patients with critical limb ischemia undergoing revascularization, showing improved amputation-free survival (HR 0.79) and limb salvage (HR 0.42) 8

Comparison to Alternative Therapies

Pentoxifylline is inferior to cilostazol and should only be considered as second-line therapy when cilostazol is contraindicated. 1, 2, 1

• Pentoxifylline provides marginal improvement in walking distance (21-29 meters pain-free, 43-48 meters maximal) 1
• Direct comparison trial showed no significant difference between pentoxifylline and placebo, while cilostazol improved both pain-free and maximal walking distance 1
• Pentoxifylline dose is 400 mg three times daily 1, 2, 1

Clinical Algorithm for Use

1. Screen for heart failure: Exclude any patient with current or history of heart failure 1, 2
2. Confirm lifestyle-limiting claudication: Patient must have intermittent claudication that impairs daily activities 1, 2
3. Initiate cilostazol 100 mg twice daily with food timing instructions 3
4. Combine with supervised exercise: Cilostazol should complement, not replace, supervised exercise therapy (30-45 minutes, ≥3 times weekly, minimum 12 weeks) 2
5. Early tolerance check at 2-4 weeks: Address adverse effects, particularly headache 3
6. Efficacy assessment at 3-6 months: Measure walking distance improvement and symptom relief 3
7. Continue if beneficial: Maintain therapy long-term if patient demonstrates improved walking capacity and quality of life 1

Special Populations

In hemodialysis patients with PAD, continuous cilostazol use reduces emergency department visits, cardiovascular events, and hemorrhagic stroke risk. 9

• Adjusted hazard ratios: 0.79 for ED visits, 0.29 for hemorrhagic stroke, 0.67 for cardiovascular events 9
• This represents an important extension of cilostazol benefits beyond claudication symptoms alone 9